Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Germline Cancer Testing in Unselected Patients With Neuroendocrine Neoplasms: A Multi-center Prospective Study.

Oluseyi Abidoye¹, Michael Golafshar², Katie Kunz²

¹Mayo Clinic Cancer Center, Arizona.

|June 4, 2026

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Landscape of clinical trials and impact of precision medicine in biliary tract cancers in the last 45 years: a systematic review and meta-analysis of biomarker-driven trials.

Translational gastroenterology and hepatology·2026

Same author

Patient Perspectives and Demographic Factors Influencing Non-Participation in a Large Genomics Study.

Mayo Clinic proceedings. Innovations, quality & outcomes·2026

Same author

Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).

Frontiers in immunology·2026

Same author

Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer.

Journal of gastroenterology·2026

Same author

Adjuvant chemotherapy in elderly colon cancer patients: when less may be more.

Journal of gastrointestinal oncology·2026

Same author

Improving Affordability in Cancer Care for Resource-Limited Settings: Highlights From <i>JCO Global Oncology</i>.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026

This summary is machine-generated.

Universal germline testing found pathogenic germline variants (PGVs) in over 15% of neuroendocrine neoplasm (NEN) patients. This supports broader genetic testing for treatment guidance and family risk assessment.

Area of Science:

Oncology
Genetics
Cancer Predisposition Syndromes

Background:

Neuroendocrine neoplasms (NENs) exhibit an increasing recognition of hereditary patterns.
The prevalence and clinical significance of pathogenic germline variants (PGVs) in unselected NEN patients are not well-established.
Current genetic testing criteria may not capture all individuals with hereditary NENs.

Purpose of the Study:

To determine the prevalence of PGVs in a diverse cohort of unselected NEN patients.
To evaluate the clinical utility of universal multi-gene panel testing for NENs.
To assess the impact of PGVs on treatment decisions and familial risk assessment.

Main Methods:

Prospective, multicenter study enrolling unselected NEN patients.

Keywords:

GERMLINE TESTING Neuroendocrine neoplasms Pathogenic germline variants

Related Experiment Videos

Last Updated: Jun 5, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Germline genetic testing using a next-generation sequencing panel of up to 84 cancer predisposition genes.

Analysis of clinical and demographic data, with variants classified as PGVs, variants of uncertain significance (VUS), or negative.

Main Results:

Pathogenic germline variants (PGVs) were identified in 15.9% of 88 unselected NEN patients.
Most frequent PGVs were in MEN1, CHEK2, MITF, and MUTYH genes, particularly in pancreatic (21.8%) and small bowel (10%) NENs.
Over 35% of PGV-positive patients did not meet current NCCN or ACMG testing criteria, highlighting the limitations of traditional guidelines.

Conclusions:

Universal germline testing in unselected NEN patients reveals a significant prevalence of clinically relevant PGVs.
These findings advocate for expanded genetic testing strategies to guide NEN management.
Broader testing facilitates improved familial risk assessment and cascade testing irrespective of traditional clinical criteria.